GNA15 and acute myeloid leukemia: In the NK-AML subgroup, subjects with high GNA15 expression showed a worse 2-year OS and RFS than subjects with low GNA15 expression (OS: 15.1% [0%-30.8%] vs 49.7% [28.1%-71.3%], P=0.0046; RFS: 24.1% [0%-49.8%] vs 49.4% [26.7%-72.1%], P=0.0409; Figures 2C, D).